<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421275</url>
  </required_header>
  <id_info>
    <org_study_id>FK_0001</org_study_id>
    <nct_id>NCT03421275</nct_id>
  </id_info>
  <brief_title>Intranasal Esketamine and Fentanyl for Pain in Minor Trauma</brief_title>
  <official_title>Intranasal Fentanyl and Esketamine for Treatment of Acute Pain in Minor Trauma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Meuronen, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital District of Helsinki and Uusimaa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intranasal esketamine, fentanyl and placebo are compared in treatment of acute pain in adult
      patients with minor trauma. Study is blinded randomized placebo-controlled parallel design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numeric rating scale (NRS) change</measure>
    <time_frame>15 minutes and 30 minutes</time_frame>
    <description>Numeric rating scale is used to measure pain intensity. Scale is from 0-10. 0 = no pain, 10 = worst imegeable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of patients with NRS change more than -2</measure>
    <time_frame>15 min, 30 min, 60 min</time_frame>
    <description>Amount of patients with NRS dropping more than 2 at time poin 15 minutes, 20 minutes and 60 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction (pain management)</measure>
    <time_frame>120 min</time_frame>
    <description>Whole experience of pain management on NRS scale from 0-10 (0 = absolutely terrible, 10 = best imagenable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>120 min</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of study drug consumed (doses)</measure>
    <time_frame>120 min</time_frame>
    <description>Amount of sturdy drug consumed as doses in the end of study period. One dose is determined by patient weight.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for rescue medication mg (oxycodone)</measure>
    <time_frame>120 min</time_frame>
    <description>Amount of oral or intramuscular oxycodone consumption in the end of study period as milligrams</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Acute Pain Due to Trauma</condition>
  <arm_group>
    <arm_group_label>Esketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous anaesthetic and analgetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fentanyl Citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous opioid analgetic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Nasal</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous &quot;Natriumklorid b. Braun 9 mg/ml&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esketamine</intervention_name>
    <description>anesthetic used as analgetic in subanesthetic doses given intranasally</description>
    <arm_group_label>Esketamine</arm_group_label>
    <other_name>Ketanest-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl Citrate</intervention_name>
    <description>intravenous fentanyl given intranasally</description>
    <arm_group_label>Fentanyl Citrate</arm_group_label>
    <other_name>Fentanyl-Hameln</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Nasal</intervention_name>
    <description>intravenous saline given intranasally as placebo</description>
    <arm_group_label>Saline Nasal</arm_group_label>
    <other_name>Natriumklorid b. Braun 9 mg/ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NRS 5 or more, minor trauma, no need for immediate iv cannulation, weight 45-115 kg

        Exclusion Criteria:

          -  pregnancy, breastfeeding, head trauma, severe chronic obstructive pulmonary disease
             (COPD), gfr under 30, liver cirrhosis, mental illness other than mild/moderate
             depression, sleep apnea, unstable coronary artery disease (CAD), unstable heart
             failure (HF), intoxication, untreated hypertension, dementia, do not understand
             Finnish, contraindication to nasal spray, allergy to any of the medications,
             bradycardia, desaturation, suspected high intracranial pressure (ICP)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Meuronen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>consultant</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Meuronen, MD,PhD</last_name>
    <phone>+35819458711</phone>
    <email>anna.meuronen@hus.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hyvink채채 Hospital</name>
      <address>
        <city>Hyvink채채</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Meuronen, MD, PhD</last_name>
      <email>anna.meuronen@hus.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital District of Helsinki and Uusimaa</investigator_affiliation>
    <investigator_full_name>Anna Meuronen, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>fentanyl</keyword>
  <keyword>esketamine</keyword>
  <keyword>ketamine</keyword>
  <keyword>analgesia</keyword>
  <keyword>acute pain</keyword>
  <keyword>minor trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

